Par Pharmaceutical has received approval from the FDA for its Abbreviated New Drug Application for Fenofibric Acid 45mg, 135mg Delayed-release Capsules, a generic version of Abbvie’s Trilipix.

Trilipix is indicated: in combination with a statin to reduce triglycerides (TG) and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal; as monotherapy to reduce TG in patients with severe hypertriglyceridemia; and as monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hypercholesterolemia or mixed dyslipidemia.

Par has begun shipping all approved strengths of the product.

For a list of available cholesterol-lowering medications by indication, see our Dyslipidemia Drug Indications chart.

For more information call (800) 828-9393 or visit